RecruitingNot ApplicableNCT04854213

PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)


Sponsor

National Cancer Institute, Naples

Enrollment

25 participants

Start Date

Oct 6, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

PRELUDE-1 study is a pilot intervention trial that aims to describe the immunologic and genetic evolutions induced by stereotactic body radiationtherapy (SBRT) treatment in oligometastatic Colorectal Cancer (omCRC) patients with two-three nodules lung-limited disease.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria7

  • Age \<80 years
  • Cytological or histological diagnosis of colorectal adenocarcinoma
  • Two or three asymptomatic lung nodules smaller than 25 mm
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • Available Formalin Fixed Paraffin Embedded (FFPE) of resected primary tumor
  • Negative pregnancy test for all potentially childbearing women
  • Patient candidates to SBRT

Exclusion Criteria8

  • Previous systemic anti-tumor treatments (allowed treatment with capecitabine or fluorouracil and radiotherapy in the neoadjuvant setting of rectal tumors with therapy terminated at least 6 months before)
  • Neutrophils \<2000/mm³ or platelets \<100.000/mm³ or hemoglobin \<9 g/dl; serum creatinine level\> 1.5 times the maximum normal value; GOT and/or GPT \>5 times the maximum normal value and/or bilirubin level \>3 times the maximum normal value
  • Previous or concomitant malignant neoplasms (excluding basal or spinocellular cutaneous carcinoma or in situ carcinoma of the uterine cervix)
  • Active or uncontrolled infections
  • Other concomitant uncontrolled diseases or conditions contraindicating the study drugs at clinician evaluation
  • Presence of brain metastases
  • Refusal or inability to provide informed consent
  • Impossibility to guarantee follow-up

Interventions

DEVICEStereotactic Body Radiation Therapy (SBRT)

Radiation treatment


Locations(1)

Istituto Nazionale Tumori - Fondazione G. Pascale

Napoli, NAPOLI, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04854213


Related Trials